Korea Extends Closely Watched Pilot Project For Rare Disease Drug Refunds Three More Years
This article was originally published in PharmAsia News
To maintain a stable supply of some multinational products for patients with rare diseases, the health ministry has extended its pilot refund system for three more years until 2015.
You may also be interested in...
At the Canaccord Genuity Global Growth Conference, the rare disease-focused biotech reiterated its goal to reach profitability in the near future with five pipeline programs potentially augmenting a portfolio of four marketed products.
SEOUL - South Korea's Ministry of Health and Welfare held a two-day forum offering a rare opportunity for Korean and foreign pharmaceutical officials to offer comments on the ministry's controversial new pricing system
Korea's Health Ministry Dismisses Likelihood Of Compulsory Licensing For Antivirals Tamiflu and Relenza
SEOUL - The South Korean government is not in a "desperate position" that would justify seeking compulsory licensing to secure more of Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) in a protracted battle against A/H1N1, the health ministry said